本页面由Tiger Trade Technology Pte. Ltd.提供服务

Ultragenyx Pharmaceutical Inc

14.75
-0.5550-3.63%
成交量:153.38万
成交额:2,293.36万
市值:14.50亿
市盈率:-2.53
高:15.39
开:15.27
低:14.73
收:15.30
52周最高:39.89
52周最低:12.73
股本:9,831.72万
流通股本:8,071.56万
量比:0.67
换手率:1.90%
股息:- -
股息率:- -
每股收益(TTM):-5.8279
每股收益(LYR):-5.8316
净资产收益率:-608.47%
总资产收益率:-24.22%
市净率:-4.98
市盈率(LYR):-2.53

数据加载中...

2024/02/14

超过5%披露

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
2024/02/14

超过5%披露

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
2024/02/13

超过5%披露

Form SC 13G - Statement of acquisition of beneficial ownership by individuals
2024/02/08

超过5%披露

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
2024/02/08

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/01/08

重要事件披露

Form 8-K - Current report
2023/12/29

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2023/12/22

重要事件披露

Form 8-K - Current report
2023/11/03

季度报告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2023/11/03

重要事件披露

Form 8-K - Current report
2023/10/24

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2023/10/23

重要事件披露

Form 8-K - Current report
2023/10/20

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2023/10/19

[补充]招股说明书

Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses
2023/10/16

重要事件披露

Form 8-K - Current report
2023/09/12

超过5%披露

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
2023/09/08

重要事件披露

Form 8-K - Current report
2023/09/07

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2023/09/05

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2023/08/04

季度报告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]